



Interim report January - September 2013

XVIVO Perfusion AB (publ)

XVIVO Perfusion is a medical technology company which develops solutions and systems for assessing the usability of organs, allowing for treatment of organs, and maintaining organs in good condition outside the body pending transplantation. Currently, the company's product Perfadex® has a market share of more than 90 percent in the traditional preservation of lungs for transplantation.

XVIVO Perfusion employs 10 people at its headquarters in Gothenburg, Sweden, and five at its office for North & South America in Denver, USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker symbol XVIVO. The Certified Adviser is Redeye, www.redeye.se.

XVIVO
PERFUSION

Sales growth remains strong and progress is made in the registration process for STEEN Solution™ in the USA

SIGNIFICANT EVENTS IN THE THIRD QUARTER

- The company had a meeting with the FDA at which it was decided that an advisory committee meeting will be held at the beginning of 2014. This is positive since an advisory committee meeting precedes a registration decision and concludes the discussion of the documentation.
- The FDA decided that the clinics included in the study may continue to transplant lungs perfused with STEEN Solution™. At the end of the quarter, a total of 52 patients in the USA had been transplanted with lungs made available through the use of Steen Solution™ and XVIVO's perfusion machine XPS™.
- Dr. Joel Cooper is to become XVIVO Perfusion's Medical Advisor. Dr. Cooper was the first surgeon in the world to carry out a successful lung transplant and is internationally recognized for his groundbreaking progress in the treatment of lung disease. Dr. Cooper will bring his expertise in clinical lung transplantation and contribute to the company's clinical development.
- An agreement to transfer contract manufacturing of STEEN Solution™ was concluded during the quarter. This will initially involve non-recurring cost of around SEK 1 million, but within one year it will result in improved gross margin on the product.

THIRD QUARTER 2013 (JUL – SEP)

- Sales increased by 19 percent in local currency. Sales were the highest ever for an individual quarter and amounted to SEK 16.8 (14.4*) million, corresponding to an increase of 17 percent in SEK.
- Operating income before depreciation and amortization (EBITDA) amounted to SEK 3.8 (-1.5*) million, corresponding to an EBITDA margin of 23 percent.
- Net income amounted to SEK 1.6 million, resulting in earnings per share of SEK 0.08.
- Cash flow from operating activities was SEK -1.5 million due to increased inventory of SEK 5.3 million.

THE PERIOD 2013 (JAN – SEP)

- Sales increased by 20 percent in local currency. Sales amounted to SEK 48.9 (42.2*) million, corresponding to an increase of 16 percent in SEK.
- Operating income before depreciation and amortization (EBITDA) amounted to SEK 10.0 (7.7*) million, corresponding to an EBITDA margin of 20 percent.

- Net income amounted to SEK 5.7 million, resulting in earnings per share of SEK 0.29.
- Cash flow from operating activities was SEK 6.4 million.

SIGNIFICANT EVENTS AFTER THE END OF THE QUARTER

- The first transplantation in Asia using STEEN Solution™ was carried out in October 2013.
- XVIVO Perfusion has decided to launch the XPS™ system in Europe in order to facilitate the use of STEEN Solution™ based on good clinical results and great interest from clinics in Europe.
- A lawsuit was filed against Vivoline on October 11, 2013 in order to safeguard XVIVO Perfusion's rights to patents for three products invented by Professor Stig Steen.

*) See page 4 for an overview of the 2013 income statement and 2012 comparative figures.

CEO'S COMMENTS



The third quarter 2013 remained strong with the highest sales to date for an individual quarter. The sales increase was in line with previous quarters, with sales up 19 percent in local currency in the quarter and up 20 percent in local currency in the year to date compared with 2012*.

STEEN Solution™ and products related to the use of this solution continue to account for a growing share of sales, comprising 14 percent of sales in the first nine months of 2013 compared with 10 percent in the same period in 2012*. The company's finances remain strong with EBITDA at a good level.

During the quarter, the company had a meeting with the FDA at which it was decided that an advisory committee meeting will be held at the beginning of 2014. The FDA's remaining questions were also discussed at the meeting. The fact that the FDA has now decided to hold an advisory committee meeting is positive for XVIVO Perfusion since it normally concludes the discussions on the documentation and precedes a registration decision. The clinics included in the study are continuing to transplant lungs that have been perfused and evaluated outside the body using STEEN Solution™ in order to accumulate clinical experience of the method. At the end of the quarter, a total of 52 patients had been transplanted at the centers included in the study. We can state that interest in STEEN Solution™ and the XPS™ at the US clinics remains high and the results in the study to date are good.

After the end of the quarter, a lawsuit was filed against Vivoline to safeguard XVIVO Perfusion's rights to

Vivoline's patents for three products invented by Professor Stig Steen. The dispute does not involve XVIVO Perfusion's own patented product STEEN Solution™. Since XVIVO takes infringements of the company's intellectual property rights seriously, the company has notified Vivoline of its infringement and has attempted to discuss a solution. After having consulted with a number of legal experts, it was felt that there was unfortunately no other option but to begin legal proceedings.

During the period, preparations began for the relocation of the contract manufacturing of STEEN Solution™. This will initially involve certain costs, but within one year it will result in an improved gross margin. It has been decided that the company's XPS™ (XVIVO Perfusion System), which was developed in and for the US market, will also be launched in Europe due to great interest. Since the need for donated lungs exceeds the availability, patients die on the waiting list. By using STEEN Solution™ and the XPS™, a larger percentage of donated organs can be used, giving more patients the opportunity to receive a lung transplant and live a longer and better life.

During the quarter, the marketing and customer service organization in the USA was enhanced. The organization is now well resourced on both sides of the Atlantic Ocean and is focused entirely on establishing the STEEN Solution™ method as the standard treatment in lung transplantation and on developing the use of STEEN Solution™ for other organs. After a strong year to date, we look forward with confidence to the final quarter of 2013 when we will work intensively on documenting STEEN Solution™ in the USA for the advisory committee meeting and on preparing for the launch of the XPS™ machine in Europe.

Magnus Nilsson, CEO

CONFERENCE CALL

CEO Magnus Nilsson will present the report in a conference call at 2 p.m. CET on Thursday, November 7, 2013. Telephone: +46 8 50336434, enter code 90670245

*) See page 4 for an overview of the 2013 income statement and 2012 comparative figures.

INCOME STATEMENT FOR 2013 AND COMPARATIVE FIGURES FOR 2012

On October 1, 2012, XVIVO Perfusion was distributed to Vitrolife's shareholders and XVIVO Perfusion's share was listed on NASDAQ OMX First North. Trade of the shares began on October 8, 2012. Comparative figures for 2012 are from Vitrolife's Transplantation segment as it was reported by Vitrolife. Figures for sales are comparable and are not

affected by the fact that XVIVO Perfusion now stands on its own. For expenses that are recorded as comparative figures, it should be taken into consideration that XVIVO Perfusion was part of the Vitrolife Group and did not have an organization (purchasing, production, quality assurance, storage, distribution, finance and administration) of its own. See the table below for the XVIVO Perfusion's 2013 actual income statement and the comparative figures from 2012.

TABLE 1. OVERVIEW OF XVIVO PERFUSION INCOME STATEMENT 2013 AND COMPARATIVE FIGURES FOR 2012 (SEK THOUSANDS)

	January – September 2013		July – September 2013	
	Xvivo Perfusion AB (publ)	Vitrolife Segment Transplantation	Xvivo Perfusion AB (publ)	Vitrolife Segment Transplantation
SEK THOUSANDS				
Net sales	48 890	42 197	16 784	14 352
Gross income	38 904	33 588	13 375	11 748
Selling expenses	-12 344	-7 189	-4 352	-3 451
Administrative expenses	-8 929	-12 825	-2 643	-7 362
Research and development costs	-10 197	-6 055	-4 513	-2 410
Other operating revenues and expenses	723	-353	825	-178
Operating income	8 157	7 167	2 692	-1 652
Depreciation and amortization	-1 819	-563	-1 137	-197
EBITDA	9 976	7 730	3 829	-1 455

THIRD QUARTER 2013 JULY - SEPTEMBER)

NET SALES

XVIVO Perfusion's net sales increased by 19 percent in local currency. Sales amounted to SEK 16.8 (14.4*) million, corresponding to an increase of 17 percent in SEK.


INCOME

Operating income before depreciation and amortization (EBITDA) amounted to SEK 3.8 (-1.5*) million, corresponding to an EBITDA margin of 23 percent.

The gross margin during the quarter was 80 (82*) percent. Selling expenses in relation to sales were 26 (24*) percent. The increase is due to additional resources supporting the continued establishment of STEEN Solution™ and the recruitment of three individuals to strengthen the sales organization. R&D costs were 27 (17*) percent of sales. This is due to increased research in new indications and production development with a goal of enhancing the gross margin. Administrative expenses decreased to 16

(51*) percent. The decrease is primarily due to last year was charged with nonrecurring costs. Net other operating revenues and expenses during the quarter was SEK 0.8 million and mainly consisted of an insurance income. During the period, SEK 2.1 million of the development

NET SALES (SEK MILLIONS) **




*) See page 4 for an overview of the 2013 income statement and 2012 comparative figures.

**) Q4 2012 and 2013 are XVIVO Perfusion's sales. All previous quarters derive from Vitrolife's Transplantation segment, as reported in Vitrolife's reporting.

costs for STEEN Solution™ were capitalized as an intangible asset. Depreciation and amortization for the period amounted to SEK 1.1 million, whereof SEK 0.8 million was written-down.

NET SALES ROLLING 12 MONTHS (SEK MILLIONS) **



CASH FLOW

Cash flow from operating activities amounted to SEK -1.5 million during the quarter and was mainly affected by changes in inventory that amounted to SEK -5.3 million. Investments amounted to SEK 2.5 million, of which SEK 2.1 million was invested in the STEEN Solution™ study in the US. The cash flow from financing activities was SEK 6.0 million and consisted of the overdraft facility utilized of SEK 6.0 million. Cash and cash equivalents at the end of the quarter amounted to SEK 3.0 million.

FINANCING

XVIVO Perfusion's total credit facilities consist of an overdraft facility that at the end of the quarter amounted to SEK 15 million, of which SEK 6.0 million was utilized. The equity/assets ratio was 80 percent at the end of the quarter.

PRODUCTION OF STEEN SOLUTION™

An agreement to transfer contract manufacturing of STEEN Solution™ was concluded during the quarter. This will initially involve a non-recurring cost of around SEK 1 million, but within one year it will result in improved gross margin on the product.

THE PERIOD 2013 (JANUARY – SEPTEMBER)

NET SALES

XVIVO Perfusion's net sales increased by 20 percent in local currency. Sales amounted to SEK 48.9 (42.2*) million, corresponding to an increase of 16 percent in SEK.

INCOME

Operating income before depreciation and amortization (EBITDA) amounted to SEK 10.0 (7.7*) million, corresponding to an EBITDA margin of 20 percent.

The gross margin during the period was 80 (80*) percent. Selling expenses in relation to sales were 25 (17*) percent. The increase is due to additional resources supporting the continued establishment of STEEN Solution™ and the recruitment of three individuals to strengthen the sales organization. R&D costs were 21 (14*) percent of sales. The increase is due to increased research in new indications and production development with a goal of enhancing the gross margin. Administrative expenses was 18 (30*) percent. The decrease is primarily due to last year was charged with nonrecurring costs. Net other operating revenues and expenses during the quarter was SEK 0.7 million and mainly consisted of an insurance income. During the period, SEK 5.5 million of the development costs for STEEN Solution™ were capitalized as an intangible asset. Depreciation and amortization for the period amounted to SEK 1.8 million whereof SEK 0.8 million was written-down.

CASH FLOW

Cash flow from operating activities amounted to SEK 6.4 million for the period. Investments amounted to SEK 8.1 million, of which SEK 5.5 million was invested in the STEEN Solution™ study in the US. The cash flow from financing activities was SEK -3.0 million and consisted of repayments on the overdraft facility. Cash and cash equivalents at the end of the period amounted to SEK 3.0 million.

OUTLOOK FOR 2013

Since the number of lungs that can be transplanted using traditional cold perfusion is not expected to increase more than the number of donated lungs, growth is expected to come primarily from warm perfusion using the STEEN Solution™ method. Therefore, the focus during the rest of the year will be on establishing the STEEN Solution™ method as the standard treatment in lung transplantation. In Europe and Australia there is an increased interest in the XPS™ system. The focus for the rest of the year will be on preparing for the XPS™ launch and establishing the STEEN Solution™ method at more clinics by using the good clinical results that have been demonstrated to date. At present, Asia, Middle East and Eastern Europe account for around five percent of the total number of lung transplants carried out in the world, but with increased economic opportunities, the number of lung transplants will increase. Establishing the STEEN Solution™ method early on in these markets will allow this development to take place faster than would otherwise be possible. There is also great

*) See page 4 for an overview of the 2013 income statement and 2012 comparative figures.

interest in the STEEN Solution™ method in the USA and main focus will be on increasing the number of clinics that use STEEN Solution™ within the framework of the clinical study in order to be able to utilize lungs that would not otherwise have been used for transplantation.

The availability of organs is the limiting factor when it comes to increasing the number of transplants of organs other than lungs. Therefore, our research and development focus will be on developing the use of the STEEN Solution™ method for other organs. The company's organization and infrastructure are complete and no major investments in these areas are expected to be necessary for the remainder of the year.

THE COMPANY IN BRIEF

OPERATIONS

XVIVO Perfusion AB is a medical technology company which develops solutions and systems for selecting usable organs and maintaining them in optimal condition pending transplantation. Today, the company's product Perfadex® has a market share of more than 90 percent in the traditional preservation of lungs for transplantation.

A great problem in transplantation healthcare is the lack of available lungs. Currently in the USA, less than 20 percent of the available donated lungs are transplanted as it is considered far too risky to transplant the remaining majority. By using XVIVO's product STEEN Solution™, the organ is cleared of harmful substances from the donor, thus creating a better environment for the organ's cells. The technology thereby allows the organ to "recover" when possible. It also allows for functional testing to be performed outside the body. In clinical use in Europe, Australia and Canada, and in a clinical trial in the USA, it has emerged that once STEEN Solution™ perfusion has been carried out, many of the organs that were initially "refused" are assessed as being usable and have been successfully transplanted into patients with end stage lung disease. Therefore the use of STEEN Solution™ has the potential to increase the total number of lung transplants.

Over the years, XVIVO has established close relationships with most of the world's lung transplant centers and has made Perfadex® a completely dominant product in its niche. XVIVO intends to make STEEN Solution™ available all over the world with the firm conviction that the number of transplants will increase as healthcare systems gain knowledge of and access to STEEN Solution™. The objective of the company is to create value for both patients and shareholders by providing a unique product in a market with great growth potential.

BUSINESS CONCEPT

XVIVO Perfusion's business concept is to increase the survival rate of patients in need of an organ transplant by providing effective products that increase the availability and survival potential of organs once transplanted..

VISION

The company's vision is to establish warm perfusion of organs with STEEN Solution™ as the standard treatment in the transplantation of lungs and other organs.

STRATEGY

XVIVO Perfusion's strategy focuses on getting lung evaluation outside the body using the STEEN Solution™ method accepted as a standard procedure. A basic precondition of the strategy is to obtain regulatory approval for STEEN Solution™ in all important markets. XVIVO Perfusion has demonstrated through published preclinical and clinical studies that warm perfusion of organs using the STEEN Solution™ method results in more available organs, thereby giving more patients the potential to have a life-saving treatment, better quality of life, socioeconomic gains, and lower morbidity and mortality. Furthermore, the company will strive to increase awareness of the STEEN Solution™ method in important groups of stakeholders and will work with key opinion leaders in the area

OTHER INFORMATION

ORGANIZATION AND PERSONNEL

At the end of quarter the number of employees was fifteen, of whom six were women and nine were men. Of these, ten people were employed in Sweden and five in the USA.

INFORMATION ON TRANSACTIONS WITH RELATED PARTIES

No transactions that have substantially affected the company's results and financial position have been carried out with related parties during the quarter.

RISK MANAGEMENT

XVIVO Perfusion is constantly working to identify, evaluate, and manage risks in different systems and processes. Risk analyses are performed continually with regard to the company's normal business activities and also in connection with activities that are outside XVIVO Perfusion's regular quality system. The most important strategic and operative risks affecting the company are described in the 2012 annual report.

SEASONAL EFFECTS

XVIVO Perfusion's sales are marginally affected by seasonal effects.

EVENTS AFTER THE END OF THE REPORTING PERIOD

No events have occurred after the end of the reporting period that significantly affect the assessment of the financial information in this report.

November 7, 2013
Gothenburg,
The Board

THIS REPORT HAS NOT BEEN REVIEWED BY THE COMPANY'S AUDITORS.

FINANCIAL REPORTS

XVIVO Perfusion's interim reports are published on the company's website, www.xvivoperfusion.com.

The Report on Operations for 2013 will be published on Friday February 7, 2014

FOR FURTHER INFORMATION, PLEASE CONTACT

Magnus Nilsson, CEO, tel: +46 31 788 21 50,
e-mail: magnus.nilsson@xvivoperfusion.com

Christoffer Rosenblad, CFO, tel: +46 31 788 21 59,
e-mail: christoffer.rosenblad@xvivoperfusion.com

The Certified Adviser is Redeye, www.redeye.se
Certified Adviser är Redeye, www.redeye.se

XVIVO Perfusion is required to publish the information in this report in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on November 7, 2013 at 8.30 am.

This is a translation of the Swedish version of the report. When in doubt, the Swedish wording prevails.

CONSOLIDATED INCOME STATEMENTS

SEK THOUSANDS	January – September 2013	July – September 2013
Net sales	48 890	16 784
Cost of goods sold	-9 986	-3 409
Gross income	38 904	13 375
Selling expenses	-12 344	-4 352
Administrative expenses	-8 929	-2 643
Research and development costs	-10 197	-4 513
Other operating revenues and expenses	723	825
Operating income	8 157	2 692
Financial income and expenses	-401	-512
Income after financial items	7 756	2 180
Taxes	-2 066	-604
Net income	5 690	1 576
Attributable to		
Parent Company's shareholders	5 690	1 576
Earnings per share, SEK	0,29	0,08
Earnings per share, SEK*	0,29	0,08
Average number of outstanding shares	19 562 769	19 562 769
Average number of outstanding shares*	19 562 769	19 562 769
Number of shares at closing day	19 562 769	19 562 769
Number of shares at closing day*	19 562 769	19 562 769

Depreciation, amortization and write downs has reduced income for the period by SEK 1 819 thousand, of which SEK 1 137 thousand for the quarter.

* After dilution. XVIVO Perfusion has one outstanding share warrant program, comprising 195 000 warrants. The net present values of the issue price in the program is higher than both the share price at closing day and the average share price for the last 12 months.

CONSOLIDATED BALANCE SHEETS

SEK THOUSANDS	Sep 30, 2013	Dec 31, 2012
ASSETS		
Goodwill	3 209	3 811
Other intangible fixed assets	79 731	75 174
Tangible fixed assets	945	748
Financial fixed assets	4 612	2 497
Inventories	18 177	13 375
Accounts receivable	6 947	8 297
Other current receivables	1 333	2 840
Liquid funds	2 962	7 776
Total assets	117 916	114 518
SHAREHOLDERS' EQUITY AND LIABILITIES		
Shareholders' equity, attributable to the Parent Company's shareholders	94 396	88 765
Provisions	4 721	2 032
Accounts payable	3 947	6 700
Overdraft	5 974	9 089
Current tax liabilities	3 542	1 885
Other short-term liabilities	478	317
Accrued expenses and prepaid income	4 858	5 730
Total shareholders' equity and liabilities	117 916	114 518
Pledged assets for own liabilities	15 250	15 250
Contingent liabilities	-	-

CONSOLIDATED KEY RATIOS

SEK THOUSANDS	January – September 2013	July – September 2013
Gross margin, %	80	80
Operating margin before R&D costs, %	38	43
EBITDA, %	20	23
Operating margin, %	17	16
Net margin, %	12	9
Equity/assets ratio, %	80	80
Return on equity, %	6	2
Income per share, SEK	0.29	0.08
Shareholders' equity per share, SEK	4.83	4.83
Share price on closing day, SEK	29.50	29.50

CONSOLIDATED CASH FLOW STATEMENTS

SEK THOUSANDS	January – September 2013	July – September 2013
Income after financial items	7 756	2 180
Adjustment for items not affecting cash flow	1 912	1 477
Paid taxes	-724	-271
Change in inventories	-5 045	-5 338
Change in trade receivables	3 025	1 624
Change in trade payables	-530	-1 158
Cash flow from operating activities	6 394	-1 486
Cash flow from investing activities	-8 141	-2 450
Cash flow from financing activities	-2 988	6 022
Cash flow for the period	-4 735	2 086
Liquid funds at beginning of period	7 776	1 156
Exchange rate difference in liquid funds	-79	-280
Liquid funds at end of period	2 962	2 962

CONSOLIDATED CHANGES IN SHAREHOLDERS' EQUITY

SEK THOUSANDS	Attributable to Parent Company's shareholders			Sum share- holders' equity
	Share capital	Restricted reserves	Non- restricted reserves and result for the year	
Shareholders' equity when the group company was created October 1, 2012	500	3 160	85 906	89 566
Total net income			-769	-769
Shift between restricted and non-restricted reserves		1 765	-1 765	0
Change in currency diff. subsidiary			-32	-32
Closing balance December 31, 2012	500	4 925	83 340	88 765
Opening balance January 1, 2013	500	4 925	83 340	88 765
Total net income			5 690	5 690
Share warrant program			127	127
Change in currency diff. subsidiary			-186	-186
Closing balance September 30, 2013	500	4 925	88 971	94 396

INCOME STATEMENTS FOR THE PARENT COMPANY

SEK THOUSANDS	January – September		July – September	
	2013	2012	2013	2012
Net sales	42 543	44 703	7 781	15 655
Cost of goods sold	-9 751	-10 014	-2 739	-4 289
Gross income	32 792	34 689	5 042	11 366
Selling expenses	-9 208	-5 057	-3 037	-2 579
Administrative expenses	-7 481	-8 319	-2 049	-4 023
Research and development costs	-9 535	-6 206	-4 313	-2 480
Other operating revenues and expenses	723	-353	825	-171
Operating income	7 291	14 754	-3 532	2 113
Financial income and expenses	-400	-1 260	-511	-570
Income after financial items	6 891	13 494	-4 043	1 543
Year end dispositions	-	-	-	-
Taxes	-1 516	-3 155	789	-3 155
Net income	5 375	10 339	-3 254	-1 612

Depreciation, amortization and write downs has reduced income for the period by SEK 1 143 thousand (277), of which SEK 907 thousand (102) for the quarter.

BALANCE SHEETS FOR THE PARENT COMPANY

SEK THOUSANDS	Sep 30, 2013	Sep 30, 2012	Dec 31, 2012
ASSETS			
Balanced expenditures for development	78 374	71 088	73 821
Patents and licences	1 313	1 335	1 294
Trademarks	31	36	35
Tangible fixed assets	429	207	184
Participation in affiliated companies	14 475	14 475	14 475
Other financial fixed assets	2 686	418	522
Inventories	4 107	2 225	3 956
Accounts receivable	3 497	5 251	4 366
Receivables from affiliated companies	11 992	9 109	8 710
Other current receivables	1 275	1 703	2 782
Liquid funds	124	2 090	4 574
Total assets	118 303	107 937	114 719
SHAREHOLDERS' EQUITY AND LIABILITIES			
Shareholders' equity	92 390	92 501	86 888
Untaxed reserves	6 288	4 025	6 288
Provisions	3 337	520	649
Overdraft	5 974	-	9 089
Accounts payable	2 877	3 359	5 250
Liabilities to affiliated companies	-	-	-
Current tax liabilities	2 795	2 949	1 733
Other short-term liabilities	4 642	4 583	4 822
Total shareholders' equity and liabilities	118 303	107 937	114 719
Pledged assets for own liabilities	15 250	-	15 250
Contingent liabilities	-	-	-

NOTE 1. ACCOUNTING PRINCIPLES

This interim report was prepared pursuant to the Swedish Annual Accounts Act and the general advice and pronouncements of the Swedish Accounting Standards Board with the exception of BFNAR2012:1 – The Annual Accounts and Consolidated Accounts (K3) unless otherwise stated. The consolidated accounts were prepared in accordance with RR1:00. The accounting principles applied are identical, unless otherwise stated below, to the accounting principles used in the preparation of XVIVO Perfusion AB's latest Annual Report.



WWW.XVIVOPERFUSION.COM

XVIVO Perfusion AB, Box 53015, SE-400 14 Göteborg, Sweden, Tel +46-31-788 21 50, Fax +46-31-788 21 69, info@xvivoperfusion.com
XVIVO Perfusion Inc., 3666 South Inca St, Englewood, CO 80110, USA, Tel: +1 303 395 9171, Fax: +1 800 694 5897